Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Arovella Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Arovella to develop a world-first iNKT cell therapy targeting cancers
News
Top 10 at 11: Lithium, gold and old news are propelling the market this morning
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: War – Gold – Oil – The ASX – Monday
Tech
ASX Tech September Winners: Sluggish September cures Wall Street’s IPO fever
Health & Biotech
ASX Biotech September Winners: Healthcare down 5pc, but experts say it’s still best sector in a recession
Health & Biotech
Weed Week: Short sellers burned as cannabis stocks stage a rebound. Where to next?
Health & Biotech
Weed Week: Growing excitement for cannabis stocks after marijuana rescheduling hopes in the US
Health & Biotech
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Experts
SUNDAY ROAST: The small caps that lit a fire under Stockhead’s experts this week
Experts
MoneyTalks: Merchant Group’s Andrew Chapman has his eye on these diagnostic biotech stocks
Health & Biotech
These were the best ASX biotechs as Health Care sprang back to life in FY23
Health & Biotech
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m+ quarterly sales
Experts
CRITERION: The ASX cancer fighters with a sting in their treatment tails
News
CLOSING BELL: At least it didn’t get any worse after lunch… right?
News
CLOSING BELL: China’s FYQ2 GDP results are more rubbery than a grubby Gold Coast weekend
Health & Biotech
